Michael Keng
Overview
Explore the profile of Michael Keng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nachar V, Adams Curry M, Kostoff D, Wood A, Farris K, Muluneh B, et al.
JCO Oncol Pract
. 2025 Jan;
OP2400475.
PMID: 39847731
Purpose: The Hematology Oncology Pharmacist Association Oral Chemotherapy Collaborative (HOPA OCC) developed practice-based tools to use in program development and improvement for the management of patients receiving oral anticancer agents...
2.
Mort J, Brighton D, DiBenedetto S, Wells L, Clark S, Reid J, et al.
Eur J Haematol
. 2024 Nov;
114(3):481-494.
PMID: 39601208
Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical...
3.
Tran V, Salafian K, Michaels K, Jones C, Reed D, Keng M, et al.
Curr Hematol Malig Rep
. 2024 Jun;
19(4):186-196.
PMID: 38888822
Purpose Of Review: Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD...
4.
Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M
Curr Hematol Malig Rep
. 2023 Dec;
19(1):1-8.
PMID: 38060085
Purpose Of Review: Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related to abnormal B cell proliferation known as B-cell ALL....
5.
Gulleen E, Holte S, Zhang Y, Mbarusha I, Mubiru D, Pedun B, et al.
Open Forum Infect Dis
. 2023 Nov;
10(11):ofad508.
PMID: 37953812
Background: Little is known about the microbiology and outcomes of chemotherapy-associated febrile illness among patients in sub-Saharan Africa. Understanding the microbiology of febrile illness could improve antibiotic selection and infection-related...
6.
Altman J, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, et al.
Blood Adv
. 2023 Oct;
7(24):7494-7500.
PMID: 37903324
High-dose cytarabine is associated with gastrointestinal and cerebellar toxicity, precluding its use for older or unfit patients with acute myeloid leukemia (AML). Aspacytarabine, an inactive prodrug of cytarabine, was evaluated...
7.
Van Galen J, Maldonado S, Grose K, Bagley F, Olivier R, Van Hoose J, et al.
Antimicrob Steward Healthc Epidemiol
. 2023 Sep;
3(1):e158.
PMID: 37771742
This quality improvement project aimed to reduce institutional incidence of infection (CDI) following autologous stem cell transplantation. CDI incidence per transplant was .17 in a baseline period and .09 following...
8.
Varadarajan I, Pierce E, Scheuing L, Morris A, El Chaer F, Keng M
Onco Targets Ther
. 2023 Jan;
16:1-16.
PMID: 36685611
Allogeneic hematopoietic cell transplantation (allo-HCT) represents an important and potentially curative treatment option for adult patients with acute lymphoblastic leukemia. Relapse continues to remain the most important factor influencing overall...
9.
Garcia J, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez L, et al.
Blood
. 2022 Nov;
141(15):1884-1888.
PMID: 36332187
No abstract available.
10.
Pierce E, Mautner B, Mort J, Blewett A, Morris A, Keng M, et al.
Curr Hematol Malig Rep
. 2022 May;
17(4):69-81.
PMID: 35616771
Purpose Of Review: Measurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential...